Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TR399 in Healthy Volunteers and Erectile Dysfunction Patients
NCT03102398Phase 2Unknown
- Sponsor
- Tritech Biopharmaceuticals Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vardenafil in erectile dysfunction (ED), sponsored by Tritech Biopharmaceuticals Co., Ltd. Primary endpoints: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 83 days and Change from baseline in IIEF-15 Erectile Function domain score at 83 days. Status: unknown.
02
Drugs
vardenafil
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT03102398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102398.